Director Maria Martinez executed a sale of 349 shares of McKesson Corp common stock on February 19, 2026, according to a Form 4 filing submitted to the Securities and Exchange Commission. The shares changed hands at $939.865 per share, resulting in a reported transaction value of $328,012. After completing the sale, Martinez is listed as directly owning 301 shares of McKesson.
The disposition comes as McKesson's share price sits close to its 52-week peak of $971.93; the stock was trading at $951.65 at the time of the report. Over the prior 12 months the healthcare distributor has produced a 59% total return for shareholders and currently trades at a price-to-earnings ratio of 27.39.
Research available through InvestingPro is cited as concluding that McKesson remains undervalued against its Fair Value estimate. The platform also offers a Pro Research Report covering MCK and more than 1,400 U.S. equities for investors seeking expanded analysis.
McKesson's most recent quarterly results for fiscal third quarter 2026 outperformed consensus estimates. The company reported adjusted earnings per share of $9.34, ahead of the $9.16 forecast. Revenue for the quarter came in at $106.16 billion, modestly topping expectations of $105.87 billion.
Despite the beats on both EPS and revenue, McKesson's stock declined in aftermarket trading, reflecting a mixed reception from the market. In the wake of the results, TD Cowen increased its price target for McKesson from $1,000 to $1,012 while retaining a Buy rating. The firm pointed to the company’s strong results, particularly in its Oncology & Manufacturer Solutions and RxTS segments, as factors behind adjusted operating income that exceeded expectations.
The Form 4 disclosure, the share-price context and recent earnings release together paint a picture of active insider activity amid elevated market valuation and recent analyst attention. The director-level sale is a discrete, documented transaction; additional context about the motivation or timing was not included in the filing.
For investors seeking deeper metrics and valuation comparisons, the InvestingPro Fair Value tools and the Pro Research Report are referenced as available resources covering MCK and a broad set of U.S. equities.